The n-of-1 clinical trial: The ultimate strategy for individualizing medicine?

Personalized Medicine

Volumn 8, Issue 2, 2011, Pages 161-173

  Lillie, Elizabeth O ^a,b   Patay, Bradley ^a,b   Diamant, Joel ^a,b   Issell, Brian ^a,b   Topol, Eric J ^a,b,c,d   Schork, Nicholas J ^a,b,c  

^a SCRIPPS HEALTH   (United States)

^b SCRIPPS TRANSLATIONAL SCIENCE INSTITUTE   (United States)

^c SCRIPPS RESEARCH INSTITUTE   (United States)

^d West Wireless Health Institute   (United States)

Author keywords

clinical equipoise; early phase trials; individualized medicine; n of 1 n remote phenotyping; single patient trial; treatment repositioning; wireless health

Indexed keywords

PLACEBO;

ARTICLE; CLINICAL TRIAL (TOPIC); INTERVENTION STUDY; MEDICAL EDUCATION; MEDICAL INSTRUMENTATION; MEDICAL RESEARCH; MOTIVATION; PATIENT MONITORING; PERSONALIZED MEDICINE; PRIORITY JOURNAL;

EID: 79952590347     PISSN: 17410541     EISSN: 1744828X     Source Type: Journal    
DOI: 10.2217/pme.11.7     Document Type: Article

References (84)

1. Jorgensen JT: Are we approaching the post-blockbuster era? Pharmacodiagnostics and rational drug development. Expert Rev. Mol. Diagn. 8(6), 689-695 (2008).
2. Jorgensen JT: New era of personalized medicine: a 10-year anniversary. Oncologist 14(5), 557-558 (2009).
3. Hu SX, Foster T, Kieffaber A: Pharmacogenomics and personalized medicine: mapping of future value creation. Biotechniques 39(10 Suppl.), S1-S6 (2005).
4. Langreth R, Waldholz M: New era of personalized medicine: targeting drugs for each unique genetic profle. Oncologist 4(5), 426-427 (1999). (Pubitemid 29508743)
5. Trusheim MR, Berndt ER, Douglas FL: Stratifed medicine: strategic and economic implications of combining drugs and clinical biomarkers. Nat. Rev. Drug Discov. 6(4), 287-293 (2007). (Pubitemid 46505879)
6. Guyatt GH, Haynes RB, Jaeschke RZ et al.: Users' guides to the medical literature: XXV. Evidence-based medicine: principles for applying the users' guides to patient care. Evidence-Based Medicine Working Group. JAMA 284(10), 1290-1296 (2000).
7. Sackett DL, Rosenberg WM, Gray JA, Haynes RB, Richardson WS: Evidence based medicine: what it is and what it isn't. BMJ 312(7023), 71-72 (1996).
8. Lauer MS, Collins FS: Using science to improve the nation's health system: NIH's commitment to comparative effectiveness research. JAMA 303(21), 2182-2183 (2010).
9. Collins FS: Research agenda. Opportunities for research and NIH. Science 327(5961), 36-37 (2010).
10. Ginsburg GS, Willard HF: Genomic and personalized medicine: foundations and applications. Transl. Res. 154(6), 277-287 (2009).
11. Kraushaar LE, Kramer A: Are we losing the battle against cardiometabolic disease? The case for a paradigm shift in primary prevention. BMC Public Health 9, 64 (2009).
12. Rich EC: The policy debate over public investment in comparative effectiveness research. J. Gen. Intern. Med. 24(6), 752-757 (2009).
13. Snyderman R, Yoediono Z: Perspective: prospective health care and the role of academic medicine: lead, follow, or get out of the way. Acad. Med. 83(8), 707-714 (2008).
14. Vogelstein B, Kinzler KW: Cancer genes and the pathways they control. Nat. Med. 10(8), 789-799 (2004). (Pubitemid 39070849)
15. Van Cutsem E, Kohne CH, Hitre E et al.: Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N. Engl. J. Med. 360(14), 1408-1417 (2009).
16. Flockhart DA, Skaar T, Berlin DS, Klein TE, Nguyen AT: Clinically available pharmacogenomics tests. Clin. Pharmacol. Ther. 86(1), 109-113 (2009).
17. Topol EJ: Pharmacy beneft managers, pharmacies, and pharmacogenomic testing: prescription for progress? Sci. Transl. Med. 2(44), 44cm22 (2010).
18. Hamburg MA, Collins FS: The path to personalized medicine. N. Engl. J. Med. 363(4), 301-304 (2010).
19. Tsapas A, Matthews DR: Using N-of-1 trials in evidence-based clinical practice. JAMA 301(10), 1022-1023; 1023 (2009).
20. Guyatt GH, Jaeschke R: N-of-1 randomized trials-where do we stand? West. J. Med. 152(1), 67-68 (1990).
21. Everitt BS, Pickler A: Statistical Aspects of The Design of Clinical Trials. Imperial College Press, London, UK (2004).
22. Gerss JW, Kopcke W: Clinical trials and rare diseases. Adv. Exp. Med. Biol. 686, 173-190 (2010).
23. Meinert CL, Tonascia S: Clinical Trials: Design, Conduct, and Analysis. Monographs in Epidemiology and Biostatistics. Oxford University Press, NY, USA, 469 (1986).
24. Barlow DH, Nock M, Hersen M: Single Case Experimental Designs: Strategies for Studying Behavior for Change (3rd Edition). Pearson/Allyn and Bacon, MA, USA, 393 (2009).
25. Guyatt G, Sackett D, Taylor DW, Chong J, Roberts R, Pugsley S: Determining optimal therapy-randomized trials in individual patients. N. Engl. J. Med. 314(14), 889-892 (1986). (Pubitemid 16126117)
26. Guyatt GH, Keller JL, Jaeschke R, Rosenbloom D, Adachi JD, Newhouse MT: The n-of-1 randomized controlled trial: clinical usefulness. Our three-year experience. Ann. Intern. Med. 112(4), 293-299 (1990). (Pubitemid 20055354)
27. Nikles J, Mitchell G, Walters J et al.: Prioritising drugs for single patient (n-of-1) trials in palliative care. Palliat. Med. 23(7), 623-634 (2009).
28. Kravitz RL, Duan N, Niedzinski EJ, Hay MC, Subramanian SK, Weisner TS: What ever happened to n-of-1 trials? Insiders' perspectives and a look to the future. Milbank Q. 86(4), 533-555 (2008).
29. Kravitz RL, Paterniti DA, Hay MC et al.: Marketing therapeutic precision: potential facilitators and barriers to adoption of n-of-1 trials. Contemp. Clin. Trials 30(5), 436-445 (2009).
30. Kraemer HC, Frank E, Kupfer DJ: Moderators of treatment outcomes: clinical, research, and policy importance. JAMA 296(10), 1286-1289 (2006). (Pubitemid 44394901)
31. Kraemer HC, Wilson GT, Fairburn CG, Agras WS: Mediators and moderators of treatment effects in randomized clinical trials. Arch. Gen. Psychiatry 59(10), 877-883 (2002).
32. Kent DM, Hayward RA: Limitations of applying summary results of clinical trials to individual patients: the need for risk stratifcation. JAMA 298(10), 1209-1212 (2007). (Pubitemid 47403108)
33. Scuffham PA, Nikles J, Mitchell GK et al.: Using n-of-1 trials to improve patient management and save costs. J. Gen. Intern. Med. 25(9), 906-913 (2010).
34. Grande GE, Todd CJ: Why are trials in palliative care so diffcult? Palliat. Med. 14(1), 69-74 (2000). (Pubitemid 30095231)
35. Abrahm JL: A Physician's Guide to Pain and Symptom Management in Cancer Patients (2nd Edition). Johns Hopkins University Press, MD, USA (2005).
36. Zucker DR, Schmid CH, McIntosh MW, DAgostino RB, Selker HP, Lau J: Combining single patient (n-of-1) trials to estimate population treatment effects and to evaluate individual patient responses to treatment. J. Clin. Epidemiol. 50(4), 401-410 (1997). (Pubitemid 27223269)
37. Huber AM, Tomlinson GA, Koren G, Feldman BM: Amitriptyline to relieve pain in juvenile idiopathic arthritis: a pilot study using Bayesian metaana lysis of multiple n-of-1 clinical trials. J. Rheumatol. 34(5), 1125-1132 (2007). (Pubitemid 46774860)
38. Senn S: Cross-over Trials in Clinical Research (2nd Edition). Wiley, Chichester, UK (2002).
39. Guyatt GH, Heyting A, Jaeschke R, Keller J, Adachi JD, Roberts RS: N-of-1 randomized trials for investigating new drugs. Control. Clin. Trials 11(2), 88-100 (1990). (Pubitemid 20136183)
40. Yelland MJ, Nikles CJ, McNairn N, Del Mar CB, Schluter PJ, Brown RM: Celecoxib compared with sustained-release paracetamol for osteoarthritis: a series of n-of-1 trials. Rheumatology 46(1), 135-140 (2007). (Pubitemid 44932801)
41. Kazdin AE: Single-Case Research Designs: Methods for Clinical and Applied Settings. Oxford University Press, NY, USA, 368 (1982).
42. Barlow DH, Hersen M: Single Case Experimental Designs (2nd Edition). Allyn and Bacon, MA, USA (1984).
43. Spiegelhalter DJ: Statistical issues in studies of individual response. Scand. J. Gastroenterol. Suppl. 147, 40-45 (1988).
44. Rochon J: A statistical model for the "n-of-1" study. J. Clin. Epidemiol. 43(5), 499-508 (1990).
45. Topol EJ: Transforming medicine via digital innovation. Sci. Transl. Med. 2(16), 16cm4 (2010).
46. Plasqui G, Westerterp KR: Physical activity assessment with accelerometers: an evaluation against doubly labeled water. Obesity (Silver Spring) 15(10), 2371-2379 (2007). (Pubitemid 350034029)
47. Reid SC, Kauer SD, Dudgeon P, Sanci LA, Shrier LA, Patton GC: A mobile phone program to track young people's experiences of mood, stress and coping. Development and testing of the mobiletype program. Soc. Psychiatry Psychiatr. Epidemiol. 44(6), 501-507 (2009).
48. Sudano I, Flammer AJ, Hermann F et al.: Auricall. A new device for a non-invasive, wireless, continuous monitoring of oxygen saturation and heart rate in patients with heart failure. Int. J. Cardiol. 129(1), 141-143 (2008).
49. Welch J, Guilak F, Baker S: A wireless ECG smart sensor for broad application in life threatening event detection. Conf. Proc. IEEE Eng. Med. Biol. Soc. 5, 3447-3449 (2004). (Pubitemid 40035390)
50. Wong LJ, Buckingham BA, Kunselman B, Istoc E, Leach J, Purvis R: Extended use of a new continuous glucose monitoring system with wireless data transmission in children with Type 1 diabetes mellitus. Diabetes Technol. Ther. 8(2), 139-145 (2006). (Pubitemid 43848036)
51. Vlassov VV, Laktionov PP, Rykova EY: Circulating nucleic acids as a potential source for cancer biomarkers. Curr. Mol. Med. 10(2), 142-165 (2010).
52. Wu H, Chen H, Hu PC: Circulating endothelial cells and endothelial progenitors as surrogate biomarkers in vascular dysfunction. Clin. Lab. 53(5-6), 285-295 (2007). (Pubitemid 46971034)
53. Zucker DR, Ruthazer R, Schmid CH: Individual (n-of-1) trials can be combined to give population comparative treatment effect estimates: methodologic considerations. J. Clin. Epidemiol. 63(12), 1312-1323 (2010).
54. Larson EB, Ellsworth AJ, Oas J: Randomized clinical trials in single patients during a 2-year period. JAMA 270(22), 2708-2712 (1993). (Pubitemid 23350968)
55. Mahon J, Laupacis A, Donner A, Wood T Randomised study of n-of-1 trials versus standard practice. BMJ 312(7038), 1069-1074 (1996). (Pubitemid 26125133)
56. Nikles CJ, Mitchell GK, Del Mar CB, Clavarino A, McNairn N: An n-of-1 trial service in clinical practice: testing the effectiveness of stimulants for attention-defcit/hyperactivity disorder. Pediatrics 117(6), 2040-2046 (2006). (Pubitemid 46071249)
57. Pope JE, Prashker M, Anderson J: The effcacy and cost effectiveness of n-of-1 studies with diclofenac compared with standard treatment with nonsteroidal antiinfammatory drugs in osteoarthritis. J. Rheumatol. 31(1), 140-149 (2004). (Pubitemid 38067536)
58. Scuffham PA, Yelland MJ, Nikles J, Pietrzak E, Wilkinson D: Are n-of-1 trials an economically viable option to improve access to selected high cost medications? The Australian experience. Value Health 11(1), 97-109 (2008). (Pubitemid 351160880)
59. Chow SC, Chang M: Adaptive Design Methods in Clinical Trials. Chapman Hall, FL, USA (2007).
60. Rausch TL, Judd TM: The development of an interoperable roadmap for medical devices. Conf. Proc. IEEE Eng Med. Biol. Soc. Suppl. 6740-6743 (2006).
61. Cepeda MS, Acevedo JC, Alvarez H, Miranda N, Cortes C, Carr DB: An n-of-1 trial as an aid to decision-making prior to implanting a permanent spinal cord stimulator. Pain Med. 9(2), 235-239 (2008). (Pubitemid 351285419)
62. Nathan PC, Tomlinson G, Dupuis LL et al.: A pilot study of ondansetron plus metopimazine vs. ondansetron monotherapy in children receiving highly emetogenic chemotherapy: a Bayesian randomized serial n-of-1 trials design. Support. Care Cancer 14(3), 268-276 (2006). (Pubitemid 43247931)
63. Woodfeld R, Goodyear-Smith F, Arroll B: N-of-1 trials of quinine effcacy in skeletal muscle cramps of the leg. Br. J. Gen. Pract. 55(512), 181-185 (2005). (Pubitemid 40361406)
64. Nikles CJ, Yelland M, Glasziou PP, Del Mar C: Do individualized medication effectiveness tests (n-of-1 trials) change clinical decisions about which drugs to use for osteoarthritis and chronic pain? Am. J. Ther. 12(1), 92-97 (2005). (Pubitemid 40516050)
65. Notcutt W, Price M, Miller R et al.: Initial experiences with medicinal extracts of cannabis for chronic pain: results from 34 'n-of-1' studies. Anaesthesia 59(5), 440-452 (2004). (Pubitemid 38578684)
66. Haas DC, Sheehe PR: Dextroamphetamine pilot crossover trials and n-of-1 trials in patients with chronic tension-type and migraine headache. Headache 44(10), 1029-1037 (2004). (Pubitemid 39532347)
67. Wegman AC, van der Windt DA, de Haan M, Deville WL, Fo CT, de Vries TP: Switching from NSAIDs to paracetamol: a series of n-of-1 trials for individual patients with osteoarthritis. Ann. Rheum. Dis. 62(12), 1156-1161 (2003). (Pubitemid 37500620)
68. Jansen IH, Olde Rikkert MG, Hulsbos HA, Hoefnagels WH: Toward individualized evidence-based medicine: fve 'n-of-1' trials of methylphenidate in geriatric patients. J. Am. Geriatr. Soc. 49(4), 474-476 (2001). (Pubitemid 32390884)
69. Haines DR, Gaines SP: N-of-1 randomised controlled trials of oral ketamine in patients with chronic pain. Pain 83(2), 283-287 (1999). (Pubitemid 29479287)
70. March L, Irwig L, Schwarz J, Simpson J, Chock C, Brooks P: N-of-1 trials comparing a non-steroidal anti-infammatory drug with paracetamol in osteoarthritis. BMJ 309(6961), 1041-1045; discussion 1045-1046 (1994).
71. Nonoyama ML, Brooks D, Guyatt GH, Goldstein RS: Ambulatory gas usage in patients with chronic obstructive pulmonary disease and exertional hypoxemia. J. Cardiopulm. Rehabil. Prev. 28(5), 323-329 (2008).
72. Hackett A, Gillard J, Wilcken B: N-of-1 trial for an ornithine transcarbamylase defciency carrier. Mol. Genet. Metab. 94(2), 157-161 (2008).
73. Martin RT, Whyte J: The effects of methylphenidate on command following and yes/no communication in persons with severe disorders of consciousness: a meta-ana lysis of n-of-1 studies. Am. J. Phys. Med. Rehabil. 86(8), 613-620 (2007). (Pubitemid 47220693)
74. Sung L, Tomlinson GA, Greenberg ML et al.: Serial controlled n-of-1 trials of topical vitamin E as prophylaxis for chemotherapy-induced oral mucositis in paediatric patients. Eur. J. Cancer 43(8), 1269-1275 (2007). (Pubitemid 46720244)
75. Baicus C, Baicus A: Spirulina did not ameliorate idiopathic chronic fatigue in four N-of-1 randomized controlled trials. Phytother. Res. 21(6), 570-573 (2007). (Pubitemid 46910236)
76. Pereira JA, Holbrook AM, Dolovich L et al.: Are brand-name and generic warfarin interchangeable? Multiple n-of-1 randomized, crossover trials. Ann. Pharmacother. 39(7-8), 1188-1193 (2005). (Pubitemid 40943167)
77. Coxeter PD, Schluter PJ, Eastwood HL, Nikles CJ, Glasziou PP: Valerian does not appear to reduce symptoms for patients with chronic insomnia in general practice using a series of randomised n-of-1 trials. Complement. Ther. Med. 11(4), 215-222 (2003). (Pubitemid 38292332)
78. Smith BJ, Appleton SL, Veale AJ, McElroy HJ, Veljkovic D, Saccoia L: Eformoterol n-of-1 trials in chronic obstructive pulmonary disease poorly reversible to salbutamol. Chron. Respir. Dis. 1(2), 63-69 (2004).
79. Suri R, Metcalfe C, Wallis C, Bush A: Predicting response to rhDNase and hypertonic saline in children with cystic fbrosis. Pediatr. Pulmonol. 37(4), 305-310 (2004). (Pubitemid 38523942)
80. Price JD, Grimley Evans J: An n-of-1 randomized controlled trial ('n-of-1 trial') of donepezil in the treatment of non-progressive amnestic syndrome. Age Ageing 31(4), 307-309 (2002).
81. Wolfe B, Del Rio E, Weiss SL et al.: Validation of a single-patient drug trial methodology for personalized management of gastroesophageal refux disease. J. Manag. Care Pharm. 8(6), 459-468 (2002).
82. Bollert FG, Paton JY, Marshall TG, Calvert J, Greening AP, Innes JA: Recombinant DNase in cystic fbrosis: a protocol for targeted introduction through n-of-1 trials. Scottish Cystic Fibrosis Group. Eur. Respir. J. 13(1), 107-113 (1999). (Pubitemid 29079229)
83. Kent MA, Camfeld CS, Camfeld PR: Double-blind methylphenidate trials: practical, useful, and highly endorsed by families. Arch. Pediatr. Adolesc. Med. 153(12), 1292-1296 (1999).
84. Mahon JL, Laupacis A, Hodder RV et al.: Theophylline for irreversible chronic airfow limitation: a randomized study comparing n-of-1 trials to standard practice. Chest 115(1), 38-48 (1999). (Pubitemid 29047052)